Daniel R. Chevallard bought $50k of LENZ
Chief Financial Officer at LENZ Therapeutics, Inc.. 2,198 shares at an average of $22.76, traded Nov 7, 2025, filed Nov 7, 2025.
Score components
- +22RoleCFO
- +7Trade size$50k at market
- +10Relative to holdingsHoldings up 69%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001815776-25-000072, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | POpen-market purchase Common Stock | +20 | $22.71 | $454 | 3,208 | Nov 7, 2025 |
| Nov 7, 2025 | POpen-market purchase Common Stock | +2,178 | $22.76 | $50k | 5,386 | Nov 7, 2025 |
Related signals
Other insiders at LENZ Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 73Notable | LENZ Therapeutics, Inc. | Daniel R. Chevallard Chief Financial Officer | $64k 7,500 shares | +139% | |
| 63Notable | LENZ Therapeutics, Inc. | Jeffrey P. George director | $50k 5,592 shares | - | |
| 81Strong | LENZ Therapeutics, Inc. | Evert B. Schimmelpennink President, CEO and Secretary | $251k 28,089 shares | +57% | |
| 13Weak | LENZ Therapeutics, Inc. | Shawn Olsson Chief Commercial Officer | $261k 10,000 shares | -68% | |
| 44Moderate | LENZ Therapeutics, Inc. | James W McCollum director | $239k 10,500 shares | - | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 224,974 shares | -19% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $5.7M 135,304 shares | -11% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $7.4M 188,094 shares | -13% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 260,713 shares | -17% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $6.5M 191,376 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.